Is 18F-FDG-PET useful for predicting R0 resection after induction therapy for initially unresectable locally advanced esophageal carcinoma?

General Thoracic and Cardiovascular Surgery

Volumn 65, Issue 8, 2017, Pages 455-462

  Sugimura, Keijiro ^a   Miyata, Hiroshi ^a   Yano, Masahiko ^a   Yanagimoto, Yoshitomo ^a   Ho, Moon Jeong ^a   Kobayashi, Shogo ^a   Takahashi, Hidenori ^a   Omori, Takeshi ^a   Ohue, Masayuki ^a   Sakon, Masato ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

18F FDG PET; Computed tomography; Endoscopy; T4

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; AGED; AORTA; ARTICLE; BRONCHUS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; ENDOSCOPY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; RADIATION DOSE; STENOSIS; TRACHEA; CANCER STAGING; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; MIDDLE AGED; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; ROC CURVE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85020184681     PISSN: 18636705     EISSN: 18636713     Source Type: Journal    
DOI: 10.1007/s11748-017-0786-9     Document Type: Article

References (23)

1. Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol. 2004;34:615–9.
2. Nishimura Y, Suzuki M, Nakamatsu K, Kanamori S, Yagyu Y, Shigeoka H. Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys. 2002;53:134–9.
3. Ohtsu A, Boku N, Muro K, Chin K, Muto K, Yoshida S, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.
4. de Manzoni G, Pedrazzani C, Pasini F, Bernini M, Minicozzi A, Giacopuzzi S, et al. Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. J Surg Oncol. 2007;95:261–6.
5. Fujita H, Sueyoshi S, Tanaka T, Tanaka Y, Matono S, Mori N, et al. Esophagectomy: is it necessary after chemoradiotherapy for a locally advanced T4 esophageal cancer? Prospective nonrandomized trial comparing chemoradiotherapy with surgery versus without surgery. World J Surg. 2005;29:25–30.
6. Ikeda K, Ishida K, Sato N, Koeda K, Aoki K, Kimura Y, et al. Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs. Dis Esophagus. 2001;14:197–201.
7. Makino T, Doki Y. Treatment of T4 esophageal cancer. Definitive chemo-radiotherapy vs chemo-radiotherapy followed by surgery. Ann Thorac Cardiovasc Surg. 2011;17:221–8.
8. Seto Y, Chin K, Gomi K, Kozuka T, Fukuda T, Tamada K, et al. Treatment of thoracic esophageal carcinoma invading adjacent structures. Cancer Sci. 2007;98:937–42.
9. Shimoji H, Karimata H, Nagahama M, Nishimaki T. Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study. World J Surg. 2013;37:2180–8.
10. Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, et al. Clinical relevance of induction triplet chemotherapy for esophageal cancer invading adjacent organs. J Surg Oncol. 2012;106:441–7.
11. Cerfolio RJ, Bryant AS. Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg. 2006;82:391–4.
12. Himeno S, Yasuda S, Shimada H, Tajima T, Makuuchi H. Evaluation of esophageal cancer by positron emission tomography. Jpn J Clin Oncol. 2002;32:340–6.
13. Kim JJ, Park JK, Moon SW. Usefulness of positron emission tomography-computed tomography in pre-operative evaluation of intra-thoracic esophageal cancer. Thorac Cancer. 2015;6:687–94.
14. Hsu WH, Hsu PK, Wang SJ, Lin KH, Huang CS, Hsieh CC, et al. Positron emission tomography-computed tomography in predicting locoregional invasion in esophageal squamous cell carcinoma. Ann Thorac Surg. 2009;87:1564–8.
15. 18F-FDG-PET). Ann Surg Oncol. 2014;21:575–82.
16. 18F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in oesophageal cancer patients? A meta-analysis. Nucl Med Commun. 2011;32:1005–10.
17. 18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg. 2009;250:888–94.
18. Society JE. Japanese Classification of Esophageal Cancer. 11th ed. Tokyo: Kanehara & Co Ltd.; 2015.
19. Karimata H, Shimoji H, Nishimaki T. Clinicopathological factors predicting R0 resection and long-term survival after esophagectomy in patients with T4 esophageal cancer undergoing induction chemotherapy or chemoradiotherapy. Surg Today. 2015;45:479–86.
20. Picus D, Balfe DM, Koehler RE, Roper CL, Owen JW. Computed tomography in the staging of esophageal carcinoma. Radiology. 1983;146:433–8.
21. Tsujimoto H, Ichikura T, Aiko S, Yaguchi Y, Kumano I, Takahata R, et al. Multidetector-computed tomography attenuation values between the tumor and aortic wall in response to induction therapy for esophageal cancer and its predictive value for aortic invasion. Exp Ther Med. 2012;3:243–8.
22. Wayman J, Chakraverty S, Griffin SM, Doyle GJ, Keir MJ, Simpson W. Evaluation of local invasion by oesophageal carcinoma—a prospective study of prone computed tomography scanning. Postgrad Med J. 2001;77:181–4.
23. Tsujimoto H, Matsumoto Y, Kumano I, Takahata R, Yoshida K, Horiguchi H, et al. Distance between the esophageal tumor and the aorta measured by using the contrast-enhanced attenuation on computed tomography for predicting this tumor invading aorta. J Gastroenterol Hepatol. 2013;28:297–302.